Rallybio(US:RLYB) Businesswire·2026-03-04 16:53Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed merger of Rallybio Corporation and Candid Therapeutics, focusing on the fairness and adequacy of the merger process for Rallybio shareholders [1] Company Overview - Rallybio Corporation (NasdaqCM: RLYB) is set to merge with Candid Therapeutics, Inc. [1] - Upon completion of the merger, Rallybio shareholders are expected to own approximately 3.65% of the combined entity [1] Legal Investigation - Kahn Swick & Foti, LLC, led by former Louisiana Attorney General Charles C. Foti, Jr., is assessing whether the merger process and terms are fair to Rallybio shareholders [1] - The firm is open to discussions regarding legal rights related to the proposed transaction, providing contact information for inquiries [1]